Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.
Clin Ther
; 39(10): 2024-2037, 2017 Oct.
Article
in En
| MEDLINE
| ID: mdl-28923291
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrans
/
Diabetes Mellitus, Type 2
/
Dipeptidyl-Peptidase IV Inhibitors
/
Medication Adherence
/
Heterocyclic Compounds, 2-Ring
/
Metformin
Type of study:
Clinical_trials
/
Guideline
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Clin Ther
Year:
2017
Document type:
Article
Country of publication:
United States